logo
The Forgotten Story Of C341 — Or Félicette — The French Feline Who Was Launched Into Space In 1963

The Forgotten Story Of C341 — Or Félicette — The French Feline Who Was Launched Into Space In 1963

Forbes20-04-2025
While the Soviets sent man's best friend into space, the French had other plans. Meet Félicette, the ... More feline astronaut history forgot.
You don't have to be a pet parent to know that dogs and cats are like night and day. The history of dogs, at least in their current form, traces back around 15,000 years. According to current scientific consensus, toward the end of the Last Ice Age, more submissive individuals within the gray wolf population began adapting to human interaction in ways they hadn't before. Many of the friendly traits these proto-dogs developed are still with us, only now, they're genetically wired to read and respond to us.
Unlike dogs, cats appear to have 'domesticated themselves,' choosing to live alongside humans while maintaining their independence, a process that began 9,000 years ago. That might sound on-brand for cat meme material, but the science backs it up. Housecat DNA remains largely unchanged from their wild ancestors, and history has shown that these furballs are never too far from flipping back into elite predator mode when the right opportunity strikes.
All of this context makes the story of France's 1960s feline space mission even heavier.
In 1947, the United States made space history with a swarm of fruit flies. Launched aboard a captured German rocket, these unusual passengers were sent to study the effects of cosmic radiation on living organisms.
As the Cold War escalated, space became the stage for geopolitical flexing. The U.S. and the U.S.S.R were aiming for more than just technological milestones. It was a brazen display of ideological one-upmanship. In 1957, the Soviets launched Laika into space, and by the early '60s, animals had become central to space programs around the world, their lives traded for data in the race beyond Earth.
This is the backdrop in which France — late to the party but eager to join the club — made a curious choice. While the Soviets sent dogs and the Americans trained primates, France turned to stray cats, plucked from the streets of Paris.
Fourteen female cats were brought in by scientists at CERMA, France's space medicine program. None of them were named. In fact, in a small attempt to keep things clinical, they were deliberately given ID numbers instead of names. It was treated as pre-launch protocol.
The cats were wired up with electrodes to monitor brain activity and put through a bootcamp of sorts. They were confined in tight containers for long periods, just to observe their reactions. Then came the centrifuge — designed to simulate the crushing G-forces of launch and re-entry.
For animals that had once stalked alleyways and rooftops, it was an abrupt shift in lifestyle. Eventually, six cats made it to the final round. One of them, a black-and-white tuxedo with the designation C341, stood out. Not because she was stronger, faster or more willing, but because she was the one who got chosen.
An unnamed stray, strapped into a capsule, headed for a once-in-a-lifetime journey past the Kármán line.
A slender Veronique AGI rocket stood poised at the Interarmy Special Vehicles Test Centre in the Algerian Sahara. There was no towering launch tower. Instead, there were four long legs holding it upright. Inside the capsule sat C341 — still unnamed, still wired up and still unaware she was a participant in a geopolitical power struggle.
The rocket lifted off just after 8 a.m. and carried her beyond the bureaucratic boundary of space, the Kármán line. She hit 9.5 g on the way up, spent a few minutes in weightlessness, then came back down under 7 g, sealed inside a capsule with no windows and no context. It lasted 13 minutes.
She flew 57 kilometers past the accepted edge of space, and minutes later, she landed upside down in the sand. When the press got hold of the story and assumed the space cat was male, they called her Félix. The scientists corrected them — Félicette. And with that, C341 finally had a name. However, it would take decades for anyone to remember it.
Félicette didn't get a reunion tour or a retirement cushion. Just a few weeks after her return, she was euthanized so scientists at CERMA could study her body. The goal was to see how spaceflight had affected her internal systems. But the results were underwhelming. Whatever they were hoping to find, they didn't. The postmortem taught them little.
In the end, she was cataloged like any other lab subject. One experiment in a series. The only cat ever sent to space, and yet, for years, barely a footnote in history. That would change. But not for a while, and not in the same way we remember Laika.
Félicette's story was rediscovered in an era that had grown more reflective about the costs of our ambitions, particularly on non-consenting, non-human participants. In 2019, a statue was unveiled in her honor at the International Space University in Strasbourg. Cast in bronze, it showed her sitting atop Earth, looking up at the stars she once flew so close to. This gesture was the best we could come up with.
While it's only human to romanticize her, part of what makes her story so tragic is how unromantic it is. No one claimed she volunteered. She was a street cat who ended up strapped into a rocket. And yet, something about her legacy painfully lingers.
This may be because cats, despite all their independence, have evolved to understand us in subtle, unsettling ways. They respond to human emotion. They know how to earn food, how to navigate social cues and how to win affection without losing autonomy. Evolution, it seems, didn't overwrite their instincts, it just rewired how they manage risk and reward in human environments.
In that sense, Félicette was the perfect subject: independent enough to survive the streets of Paris, adaptable enough to tolerate confinement and familiar enough for her absence to finally sting — just a few decades too late.
While Félicette's story is a slow burn, the cost of human progess has turned into a display of the snowball effect in action. Take the Climate Change Worry Scale to learn more about your attitude toward our collective actions.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Why does your mind goes 'blank'? New brain scans reveal the surprising answer
Why does your mind goes 'blank'? New brain scans reveal the surprising answer

Yahoo

timean hour ago

  • Yahoo

Why does your mind goes 'blank'? New brain scans reveal the surprising answer

When you buy through links on our articles, Future and its syndication partners may earn a commission. You look up from your phone screen and suddenly realize you weren't thinking about anything. It's not a lapse in memory or a daydream; it's literally a moment when you're not thinking of anything at all. Neuroscientists have a term for it — mind blanking — which they define as a brief, waking state when conscious thought simply stops. Scientists used to think our waking minds were always generating thoughts, but recent research shows that's not the case. Mind blanking is now recognized as a distinct conscious state associated with changes in arousal, which in neuroscience refers to alertness and responsiveness to stimuli. Studying this curious state could shed light on how consciousness works, some researchers think. "For some, it's kind of a blip in the mind, and suddenly there's nothing," Thomas Andrillon, a neuroscience researcher at the French National Institute of Health and Medical Research and the Paris Brain Institute, told Live Science. "But not with that feeling, 'There was something that I forgot.'" Often, people are unaware of the lapse until they are prompted to answer "What were you just thinking about?" "When we interrupt them randomly," Andrillon continued, "it's clear it's more frequent than what people realize." Although the frequency of this phenomenon varies among individuals, various studies suggest about 5% to 20% of a person's waking hours may be spent in this state. Related: Super-detailed map of brain cells that keep us awake could improve our understanding of consciousness An investigation of 'mind blanking' In a study published in the July issue of the journal Trends in Cognitive Sciences, Andrillon and his team used electroencephalography (EEG) — which involves placing electrodes on participants' heads — to measure brain activity while people experienced lapses in attention, such as mind wandering or mind blanking. Mind wandering occurs when people's thoughts drift to tasks or ideas unrelated to the one at hand, while mind blanking involves the absence of all thought. While wearing EEG caps, participants watched numbers flash rapidly on a display screen. They were instructed to press a button every time a number appeared except for 3, which they were told to skip. This task tests how quickly people react when a response is required and how well they can inhibit that response, when necessary. Because most of the presented numbers required a response, people often pressed the button by mistake when they saw a 3 onscreen. The researchers paused the task once a minute to ask what the participants were thinking, finding that they were either focused on the task, their mind was wandering, or they were experiencing a "mind blank." Participants pressed the button more quickly when their minds were wandering, whereas their responses slowed noticeably during mind blanking, suggesting these two mental states are distinct. Brain activity told a similar story. The EEG data showed that the participants' brain activity tended to slow down slightly more when their minds were blank than when they were wandering, compared to the baseline of their paying attention. 'The connectivity changes as if the inner workings of the brain were specific, in a way, to that state," Andrillion said. EEG data is great for tracking rapid changes in brain activity, but it can't pinpoint exactly which brain regions are involved. That's in part because it records brain waves through the skull, and the signals blur as they make their way through the brain tissue, fluid and bone. Andrillon explained it's like listening through a wall. You can tell if a group inside is noisy or quiet, but you can't tell who is talking. The EEG results from the study suggest that during mind blanking, the brain's activity slows down globally, but the technique couldn't identify specific areas. That's where functional MRI (fMRI) came in. Related: 'Hyper-synchronized' brain waves may explain why different psychedelics have similar effects, rat study reveals Hypersynchronization fMRI provides a clearer view of which regions are active and how they interact, but its tracking speed is slower because the technique tracks bloodflow, rather than directly following brain signals. fMRI is more like peeking into the room and seeing who's talking to whom, but not knowing precisely when, Andrillion said. Study co-author Athena Demertzi, a neuroscience researcher at the GIGA Institute-CRC Human Imaging Center at the University of Liège in Belgium, led the fMRI portion of the study. As people rested in an fMRI scanner with no particular task at hand, Demertzi and her team periodically asked what they were thinking. The results were surprising: when people reported mind blanking, their brains showed hyperconnectivity — a global, synchronized activity pattern similar to that seen in deep sleep. Typically, when we are awake and conscious, our brain regions are connected and communicating but not synchronized, as they appear to be during mind blanks. "What we think happens in the case of mind blanking is that the brain is pushed a little bit toward the side of synchronization," Andrillon said. "That might be enough to disrupt these sweet spots of consciousness, sending our mind to blank." Research into mind blanking is still in its early stages, but Andrillon and Demertzi noted that its similarity to brain patterns seen during deep sleep may offer an important clue as to its function. Deep sleep, also known as slow-wave sleep, coincides with important cleanup work for the brain. It clears away accumulated waste, cools the brain, conserves energy and helps reset the system after a full day of mental activity. RELATED STORIES —Why do we forget things we were just thinking about? —Electronic' scalp tattoos could be next big thing in brain monitoring —'Hyper-synchronized' brain waves may explain why different psychedelics have similar effects, rat study reveals Andrillon and Demertzi suggested mind blanking may act as a mini-reset while we're awake. Demertzi said it's like "taking five to steam off" or "to cool your head." Early studies in Demertzi's lab suggest sleep-deprived people report more mind blanks, adding support to this idea. Both researchers stressed that this state is likely a way for the brain to maintain itself, though "it's not ideal for performance," Andrillon said. Andrillon believes it's possible but unlikely that there are people who have never experienced mind blanking. Detecting a mind blank can be a challenge. "It can require being interrupted," Andrillon said, "to realize, 'OK, actually, there was no content.'"

You might inhale ight Inhale 68,000 microplastics per day
You might inhale ight Inhale 68,000 microplastics per day

UPI

time3 days ago

  • UPI

You might inhale ight Inhale 68,000 microplastics per day

The French team used high tech equipment to measure concentrations of microplastics in 16 air samples from their own apartments and cars. Photo by Adobe Stock/HealthDay July 31 (UPI) -- Scientists say the average person may be inhaling microscopic, lung-penetrating plastic particles at a rate that's 100 times what was previously assumed: 68,000 per day. "Everywhere we look, we find microplastics, even in the air we breathe inside our homes and cars," said the French team that conducted the study. "The biggest concern is how small these particles are, completely invisible to the naked eye. We inhale thousands of them every day without even realizing it." The study was led by Nadiia Yakovenko of the University of Toulouse and published July 30 in the journal PLOS One. As the researchers noted, prior research has sought to estimate how many microplastics people breathe in daily. But those studies focused on relatively large particles -- about 20 to 200 micrometers in diameter. Yakovenko's team tracked even more minute plastic particles, ranging from 1 to 10 micrometers across - far smaller than a human hair. Their incredibly small size means these invaders can penetrate deep into the lungs. The French team used high tech equipment to measure concentrations of microplastics in 16 air samples from their own apartments and cars. They found that in their apartments, an average of 528 microplastic particles per cubic meter floated in the air they breathed. That rose to 2,238 particles per cubic meter for car interiors, tested under normal driving conditions. Most (94%) of these particles were very tiny -- between 1 to 10 micrometers in diameter. Yakovenko's team estimated that people breathe in 3,200 larger (10 to 300 micrometers in diameter) microplastic particles per day and 68,000 smaller ones (1 to 10 micrometers). The findings point to "indoor air as a major and previously underestimated exposure route of fine particulate microplastic inhalation," the researchers said. Just how harmful are these microplastics? The jury is still out on that. However, in a study presented in April at a meeting in Chicago of the American College of Cardiology, researchers from Case Western Reserve School of Medicine in Cleveland reported that high blood pressure, diabetes and stroke rates are higher in coastal or lakefront areas of the U.S. with greater concentrations of microplastics in the environment. Research presented at meetings is typically considered preliminary, until published in a peer-reviewed journal. Microplastics might even be harming the brain. In a study published in 2024, researchers in Germany and Brazil found that 8 of 15 autopsied adults had microplastics detected within their brain's smell centers, the olfactory bulb. Particles have also been detected in human lungs, intestines, liver, blood and testicles, and even in semen. More information Find out more about microplastics at Stanford University. Copyright © 2025 HealthDay. All rights reserved.

Pandemic darlings Moderna, BioNTech are now on two different paths
Pandemic darlings Moderna, BioNTech are now on two different paths

CNBC

time3 days ago

  • CNBC

Pandemic darlings Moderna, BioNTech are now on two different paths

The Covid-19 pandemic turned Moderna and BioNTech into household names almost overnight. Now the two companies are on different paths. Both Moderna and BioNTech helped pioneer mRNA, or messenger RNA, technology. Moderna staked its entire identity around mRNA, while BioNTech saw it as one piece of a broader portfolio focused on immunology and oncology. The pandemic gave both companies a chance to prove mRNA's promise of using the body's own immune system to protect against viruses or treat diseases. Covid vaccines have generated roughly $45 billion in sales for each company, earning them each about $20 billion since their rollout in late 2020. But despite parallel booms after the pandemic, the vaccine makers have since taken their businesses in different directions — and Wall Street has noticed. The two companies have spent their Covid vaccine windfall differently: Moderna doubled down on its mRNA pipeline, while BioNTech used the money to do deals and diversify, including into one of the hottest emerging areas of cancer drugs. Today, Moderna has about $8.4 billion in cash; the German-based BioNTech has €15.9 billion (or $18.2 billion). The divergence of the two companies is even more stark in their stock performance. Over the past year, Moderna shares have slid about 72%; BioNTech shares have gained nearly 29%. "Just their name was made based off the pandemic and the vaccines that they very quickly brought to people around the world to help get us through that period of time," said Evercore ISI analyst Cory Kasimov. "But the approach they're taking now and the outlook for these two companies is distinctly different at this point." Investors will get a fresh look at both companies' performance as they post quarterly results in the coming days. Moderna is set to report Friday morning, followed by BioNTech on Monday morning. Moderna used its Covid cash to build out its mRNA portfolio, particularly vaccines. It invested in shots for flu, RSV and lesser-known viruses like cytomegalovirus and norovirus. "From our perspective, the pandemic really showed that the science of what we're doing worked, and the natural sort of response to that was to continue down that path and do more," said Moderna President Stephen Hoge. Funding such a large pipeline wasn't cheap. The company has started slashing expenses as sales of its Covid vaccine slide and its RSV vaccine struggles to find a foothold. But the clock is running, said Leerink analyst Mani Foroohar. "We're moving into a time where being a vaccine company is going to be more expensive, tedious and onerous," Foroohar said, citing changes at the Food and Drug Administration under the leadership of Health and Human Services Secretary Robert F. Kennedy Jr., who has expressed skepticism about vaccines. Foroohar in 2022 pointed out what he saw as a Shakespearean tragic flaw in Moderna's business model. That shortcoming, in his view, is that Moderna scaled its pipeline assuming mRNA technology would be the tool for all problems instead of a solution for some problems. Hoge said Moderna's "really good at making mRNA medicines" and decided to focus on doing that. "The reality is that we think over the last 10 years, that focus has actually made us successful, and in the pandemic, it certainly had a big impact and obviously was something that sets us up for the more diverse pipeline we have right now," Hoge said. "So we recognize that we may be going through some cycles, but we're pretty confident in the long-term trajectory we're on, and we're looking forward over the years ahead to showing with all these additional medicines what we're really capable of." Meanwhile, BioNTech decided to use the proceeds from its Covid vaccine to diversify. Out of the limelight as partner Pfizer took the lead on selling the companies' shot, BioNTech expanded into promising new cancer technologies. Most importantly, it acquired a bispecific antibody targeting the proteins PD-L1 and VEG-F. That technology promises to build on – and possibly best – the success that Merck has found with Keytruda, a cancer drug with nearly $30 billion in sales last year alone. That thesis still needs to be proven in large, global clinical trials, but BioNTech is already seeing that deal pay off. Bristol Myers Squibb in June announced it would pay up to $11 billion to partner with BioNTech to codevelop the experimental drug, which BioNTech acquired for a fraction of that. BioNTech in 2023 initially paid Biotheus $55 million up front to license the drug outside China before acquiring the company outright earlier this year for up to $1 billion. "[BioNTech] found an asset, they developed it, and then they got a pharma partner, it's like a dream," said BMO analyst Evan David Seigerman. "So they're really strategic in that, and I think they're adding a lot of diversification, which makes the story a lot less risky if you're just focused on mRNA, vaccines and Covid, and that's super risky, in my view." At the same time, hopes are high that BioNTech's bispecific antibody drug will work, meaning any disappointment ahead could hurt the stock. Investors are watching forthcoming Phase 3 trial results from Summit Therapeutics, which is testing a similar drug for lung cancer. Those data could help — or hurt — BioNTech's stock while it awaits data from its own studies, which could take until 2028. For Moderna, investors want to see if sales of its Covid and RSV vaccines can rebound. The company is also seeking FDA approval for an mRNA flu shot. But at this point, the most intense focus is on Moderna's Phase 3 trial for a personalized cancer treatment for melanoma, said RBC Capital Markets analyst Luca Issi. Moderna may be able to share the first interim data as soon as next year, Hoge said, though the company can't promise an exact date since it's an event-driven study. That means enough people in the trial need to relapse before Moderna can analyze whether its treatment kept cancer from returning longer. If the treatment succeeds, it could launch in 2027 or 2028, Hoge said. That leaves Moderna largely dependent on its vaccines until then. An ongoing patent dispute over Moderna's Covid-19 shot could also eat into the company's cash, analysts say, adding they expect the legal proceedings to play out next year. Time will tell whether the divergent strategies win over Wall Street long term.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store